Painreform Stock Based Compensation from 2010 to 2026
| PRFX Stock | USD 2.90 0.02 0.69% |
Stock Based Compensation | First Reported 2019-03-31 | Previous Quarter 56 K | Current Value 56 K | Quarterly Volatility 155.1 K |
Macro event markers
Review Painreform financial statements over time to add context on performance and capital structure. It connects Depreciation And Amortization of 13.7 K, Interest Expense of 12 K or Selling General Administrative of 2.4 M and ratios such as Price To Sales Ratio of 2.05, Dividend Yield of 0.0 or PTB Ratio of 0.16 with Painreform Valuation and Volatility context.
Painreform | Stock Based Compensation | Build AI portfolio with Painreform Stock |
Analyzing Painreform's Stock Based Compensation over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Stock Based Compensation has evolved provides context for assessing Painreform's current valuation and future prospects.
Latest Painreform's Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of Painreform over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. Painreform's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Painreform's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
| Timeline |
Painreform Stock Based Compensation Regression Statistics
| Arithmetic Mean | 269,130 | |
| Geometric Mean | 78,972 | |
| Coefficient Of Variation | 148.12 | |
| Mean Deviation | 305,933 | |
| Median | 38,000 | |
| Standard Deviation | 398,626 | |
| Sample Variance | 158.9B | |
| Range | 1.4M | |
| R-Value | 0.63 | |
| Mean Square Error | 102.6B | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 49,594 | |
| Total Sum of Squares | 2.5T |
Painreform Stock Based Compensation History
Other Fundumenentals of Painreform
Painreform Stock Based Compensation component correlations
Click cells to compare fundamentals
About Painreform Ltd
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel. Painreform is traded on NASDAQ Exchange in the United States. The profile for Painreform integrates fundamentals, price behavior, and sector exposure. Market-sensitive characteristics amplify cycle exposure. Painreform has a market cap of 1.87 M, ROE of -127.65%. 
Rifka Kats · Member of Macroaxis Editorial Board
Methodology
Unless otherwise specified, financial data for Painreform is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Painreform (USA Stocks:PRFX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO) as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Painreform is covered by 1 analyst. Representative analyst firms may include HSBC Global Research, Wells Fargo Securities, Goldman Sachs, Guggenheim Securities, RBC Capital Markets, among others. Updates may occur throughout the day.
Painreform Stock is Curated By:
Rifka Kats · Member of Macroaxis Editorial BoardAlso Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Painreform Stock Analysis
A structured review of Painreform often starts with core financial statements and trend context. Ratios and trend metrics help frame Painreform's operating context. Key reports that frame Painreform Stock are listed below:Review Painreform Correlation against competitors for Painreform. This provides competitive positioning context. To learn how to invest in Painreform Stock, please use our How to Invest in Painreform guide.Analysis related to Painreform should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
The market value of Painreform is measured differently than book value, which reflects Painreform accounting equity. Painreform's market capitalization is 1.87 M. A P/B ratio of 0.25 suggests Painreform trades near or below book value. Intrinsic value is an analytical estimate of Painreform's underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
Note that Painreform's intrinsic value and market price are different measures derived from different inputs. For Painreform, key inputs include a P/B ratio of 0.25, and ROE of -127.65%. Market price reflects the current exchange level formed by active bids and offers.